It is worth noting that the neuroblastoma mouse model driven by MYCN/ALKF1174L and C-MYC had even better outcomes following indisulam treatment than the PDX and cell line–generated models, which are conducted in immunodeficient mice. This evidence concerns the gene MYC and neuroblastoma.